Company / Free Cash Flow
Idexx Laboratories Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$1.1B
FY2025
5-year range
$394.1M / $1.1B
FY2021-FY2025
Trend
+30.8%
vs FY2024
Sector context
#28 of 145
Health Care
What the data says
Idexx Laboratories's free cash flow of $1.1B is higher than 81% of companies in the Health Care sector (FY2025). Free Cash Flow has increased for 3 consecutive years, from $394M in FY2022 to $1.1B in FY2025.
Based on SEC 10-K filings.
$1.1B in FY2025 with a 5-year CAGR of +14.3%. Top quartile in the Health Care sector.
Improved from $773M to $1.1B over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- +38.9%
- 5-Year CAGR
- +14.3%
- 10-Year CAGR
- -
Sector benchmark
Top 19% in Health CareTop 19% of 145This company $1.1B Sector average $770.9M
▼
+37.1% above sector average
Key checks
Key Insights
- Idexx Laboratories's free cash flow has grown for 3 consecutive years.
- 5-year CAGR of +14.3%, indicating consistent growth.
- In FY2025, free cash flow increased 30.8% year-over-year.
- Ranks #28 out of 145 companies in the Health Care sector.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 4.60 (safe zone, above 2.9 threshold)
- Strong profit margin: 24.6%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 65.8%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.1B | +30.8% |
| FY2024 | $808.1M | +4.6% |
| FY2023 | $772.9M | +96.1% |
| FY2022 | $394.1M | -38.0% |
| FY2021 | $636.0M | +17.5% |
| FY2020 | $541.1M | +77.9% |
| FY2019 | $304.2M | +7.0% |
| FY2018 | $284.3M | -4.9% |
| FY2017 | $298.9M | +9.0% |
| FY2016 | $274.2M | +97.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026